Regarding PARP inhibitors, the OlympiA trial was able to demonstrate an improved invasive disease-free survival among patients with high-risk, HER2-negative early breast cancer and germline BRCA1/2 pathogenic variants receiving an adjuvant PARP inhibitor (Olaparib)51. Here, BRCA1 is linked to breast carcinoma.